Baricitinib in Idiopathic Granulomatous Mastitis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions

Mastitis ChronicIdiopathic Granulomatous Mastitis

Interventions

DRUG

Baricitinib

Baricitinib administered orally

Trial Locations (1)

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER